NASDAQ · IVVD
Invivyd, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IVVD: Nov 5, 2026
Invivyd, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.11. The reported EPS for the same quarter last year was $-0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Dec 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Mar 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Zacks- MarketBeat · Oct 4, 10:02 PM EDTInvivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval3 Small-Cap Biotechs With Binary Catalysts on the CalendarInvivyd (NASDAQ:IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accele
- RTTNews · Oct 2, 12:13 PM EDTWeekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) – The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov
- RTTNews · Sep 29, 7:25 AM EDTInvivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial(RTTNews) – Invivyd, Inc. (IVVD) said its investigational COVID-19 monoclonal antibody VYD2311 demonstrated favorable safety and tolerability compared with an mRNA-based COVID-19 vaccine in the Phase 3 LIBERTY study.
- RTTNews · Sep 29, 7:18 AM EDTInvivyd's VYD2311 Shows Favorable Safety Profile In Phase 3 COVID Study(RTTNews) – Tuesday, Invivyd (IVVD) said its investigational COVID-19 antibody VYD2311 demonstrated favorable safety and tolerability compared with an mRNA-based COVID-19 vaccine in the Phase 3 LIBERTY study.
- MarketBeat · Sep 13, 10:50 AM EDT3 Small-Cap Biotechs With Binary Catalysts on the CalendarFor small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision. When that momen
- RTTNews · Sep 1, 8:49 AM EDTInvivyd Names Chairman Marc Elia CEO, Adds New Directors(RTTNews) – Invivyd, Inc. (IVVD), the U.S. biotechnology company focused on antibody therapies for viral disease, Tuesday announced the appointment of Marc Elia as Chief Executive Officer and he will continue to serve as Chairman of the Board.
- Zacks · Aug 13, 6:05 PM EDTInvivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue EstimatesInvivyd, Inc. (IVVD) delivered earnings and revenue surprises of +6.67% and -13.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 12, 6:15 PM EDTRenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue EstimatesRenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 7:10 PM EDTSkinHealth Systems Inc. (SKIN) Reports Q2 Loss, Lags Revenue EstimatesSkinHealth Systems Inc. (SKIN) delivered earnings and revenue surprises of +50.00% and -1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 6, 11:57 AM EDTFDA To End Emergency Use Authorization Of Invivyd's PEMGARDA In COVID-19; Stock Down(RTTNews) – Invivyd Inc. (IVVD), a pharmaceutical company developing antibody therapies, on Monday announced the receipt of a notice of termination for the emergency use authorization of PEMGARDA in the prevention of COVID-19.
- RTTNews · Jun 16, 10:09 AM EDTInvivyd Completes Enrollment In Phase 3 LIBERTY Trial Of VYD2311 For COVID-19(RTTNews) – Invivyd, Inc. (IVVD), a commercial-stage biopharmaceutical company, announced completion of participant enrollment in the Phase 3 LIBERTY clinical trial of VYD2311 for the COVID-19 indication.
- RTTNews · Jun 10, 7:04 AM EDTInvivyd Doses First Participant In Phase 3 LIBERTY Trial Of VYD2311 In COVID-19(RTTNews) – Invivyd, Inc. (IVVD) announced on Tuesday that the first participant in its Phase 3 LIBERTY trial has been dosed with VYD2311, the company's investigational monoclonal antibody candidate for COVID-19. Company Profile
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Invivyd, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.